Access Program Information
Triclabendazole is a benzimidazole compound used as a systemic antihelmintic in veterinary
practice. Triclabendazole is considered to be a second-line drug for parasites and is used
when other preferred agents cannot be used because they are ineffective or because adverse
reactions limit their use. Although Triclabendazole is widely used in developing countries
for the treatment of parasites it is not approved by the FDA for this treatment in the US.
It is currently being distributed in the US through a special arrangement with the FDA and
the manufacturer on an individual patient approval basis. This arrangement requires that a
single patient Investigational New Drug (IND) be obtained from FDA for each patient
requiring Triclabendazole. Upon approval by FDA, the manufacturer (Novartis) will ship the
drug directly to the prescribing physician.